Dr. Meuleman is Director of Investments at San Francisco-based Illumina Ventures, which manages a $200M life sciences VC fund investing primarily in tools, diagnostics and therapeutics companies with a strong emphasis on genomics. Prior to Illumina Ventures, Dr. Meuleman worked at Illumina, Inc. in various roles throughout the organization including R&D, Product Development, and Corporate Development. A physical chemist by training, he began his career in life sciences as first hire for Oxford University spin-out Oxamer, a company founded in 2003 by Prof. Sir Edwin Southern, where he led the development a benchtop DNA microarray fabrication platform. Following the company’s incorporation within Oxford Gene Technology in 2005, he continued working alongside Prof. Southern leading R&D programs in areas such as single cell gene expression analysis and novel applications for DNA microarrays. He obtained his undergraduate and Master’s degree in Chemistry from the University of Ghent, Belgium; a PhD in Chemical Engineering from the University of Newcastle, U.K; and an MBA from the University of Cambridge, U.K.